Ardelyx Bets Big On Tenapanor’s Potential, Despite Side Effect Concerns

Unwinding NHE3 partnership with AstraZeneca, Ardelyx plans to move first-in-class agent into Phase III in IBS-C while seeking more tolerable dosing regimen for late-stage development in hyperphosphatasia.